Literature summary for 3.4.24.86 extracted from

Ringel, J.; Jesnowski, R.; Moniaux, N.; Luettges, J.; Ringel, J.; Choudhury, A.; Batra, S.K.; Kloeppel, G.; Loehr, M.
Aberrant expression of a disintegrin and metalloproteinase 17/tumor necrosis factor-alpha converting enzyme increases the malignant potential in human pancreatic ductal adenocarcinoma (2006), Cancer Res., 66, 9045-9053.

Search for more literature for 3.4.24.86

Application

Application	Comment	Organism
medicine	ADAM17/TACE might be an important therapeutic target. The blocking of ADAM17/TACE expression and/or the evaluation and development of specific TACE inhibitors might have therapeutic potential even in later stages of cancer. Furthermore, ADAM17/TACE might be useful as a diagnostic marker of pancreatic cancer to distinguish between PDAC and chronic pancreatitis. Aberrant ADAM17/TACE expression might be a diagnostic and therapeutic target in human pancreatic ductal adenocarcinoma	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
tumor necrosis factor-alpha protease inhibitor	-	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
pancreas	ADAM17/TACE mRNA is expressed in 3 of 10 normal pancreatic tissues, 6 of 8 samples from patients with chronic pancreatitis	Homo sapiens	-
pancreatic cancer cell line	ADAM17/TACE mRNA is expressed in 10 of 10 PDAC tissues. ADAM17/TACE mRNA expression is down-regulated in pancreatic cancer cells arrested in G2 -M phase. Critical involvement of ADAM17/TACE in the invasion behavior of pancreatic cancer cells	Homo sapiens	-
pancreatic ductal adenocarcinoma cell	ADAM17/TACE mRNA is expressed in 10 of 10 PDAC tissues. ADAM17/TACE expression is a later event in progression of pancreatic intraepithelial neoplasia to pancreatic ductal adenocarcinoma	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
ADAM17/tumor necrosis factor-alpha (TNF-A)converting enzyme	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)